BRTX logo

BRTXBioRestorative Therapies Inc

$0.3506
$0.004
(1.05%)
Today
Closed $0.376
$0.0254
(6.75%)
Overnight
Updated: 10:14 PM EDT
Mkt Cap$9.68M
Vol439,162.00
40

Bearish Sentiment

How do you feel about BRTX?

News
all
press releases
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX) Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX) PR Newswire MIAMI, May 27, 2026 Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value...
PR Newswire
News Placeholder
More News
News Placeholder
What Makes Biorestorative Therapies (BRTX) a New Buy Stock
Biorestorative Therapies (BRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
News Placeholder
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of +36.67% and -53.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -38.89% and -14.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +93.35% and +16.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of +60.00% and +2.94%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing
Biorestorative Therapies (BRTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks
News Placeholder
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading 5.7% Higher - Here's Why
BioRestorative Therapies (OTCMKTS:BRTXQ) Trading 5.7% Higher - What's Next...
MarketBeat
News Placeholder
BioRestorative Therapies (OTCMKTS:BRTXQ) Stock Price Down 4.5% - Here's What Happened
BioRestorative Therapies (OTCMKTS:BRTXQ) Shares Down 4.5% - What's Next...
MarketBeat
News Placeholder
Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of +13.51% and -90.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
<
1
2
...
>

Advertisement|Remove ads.